Corporate News

2024

25 September

Interim Report

20 September

DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners

09 September

Notice of results

28 August

CARDIO inCode-Score® presentation on polygenic risk of Coronary Heart Disease at 2024 European Society of Cardiology (ESC) Annual Congress, London

27 June

Result of AGM

05 June

Posting of Annual Report and Notice of Annual General Meeting

03 June

Final Results

23 May

Notice of results

01 May

CARDIO inCode-Score® presentation at European Society of Cardiology Preventive Cardiology Congress

26 April

Grant of Options & Surrender of Existing Options

04 April

CARDIO inCode-Score® US study publication

21 March

New NICE Guidance for Ovarian Cancer

09 February

Holding(s) in Company

15 January

Holding(s) in Company

11 January

Holding(s) in Company

11 January

Holding(s) in Company

09 January

Result of GM and Total Voting Rights

2023

28 December

Result of Retail Offer

21 December

Result of Placing and Subscription

21 December

Retail Offer to raise up to £1.00 million via Bookbuild Platform

21 December

Placing and Subscription

29 November

GENinCode to transition CARDIO inCode-Score (CIC-SCORE) 510(k) FDA submission to De Novo pathway

29 November

Change of Adviser

12 October

ShareSoc investor presentation

20 September

Interim report

13 September

Notice of results

30 August

CARDIO inCode® study

16 August

Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)

19 July

Collaboration with US healthcare provider

30 June

Result of AGM

08 June

Posting of Annual Report to Shareholders and Notice of Annual General Meeting

06 June

Final Results

05 June

Notice of results

22 May

CARDIO inCode® study for risk of incident Coronary Heart Disease to be presented at European Society of Cardiology Annual Meeting in Amsterdam

15 May

Collaboration with University Clinic Dresden for implementation of LIPID inCode®

02 May

NHS accelerates implementation of LIPID inCode® testing of patients suffering with hypercholesterolemia and familial hypercholesterolemia

03 April

US CPT PLA Code Granted for CARDIO inCode-SCORE (CIC-SCORE)

13 March

Statement re: Silicon Valley Bank

03 January

Approval of California state license and CLIA certification opens US market

2022

22 November

Issue of Share Options

03 November

British Medical Journal publication

10 October

Holding(s) in Company

27 September

Interim results for six months ended 30 June 2022

07 September

Notice of results

26 July

NHS implementation of Lipid inCode®

23 June

Result of Annual General Meeting

23 May

Posting of Annual Report to Shareholders and Notice of Annual General Meeting

17 May

Final Results

03 May

Notice of results

06 April

Director appointment

23 March

Collaboration with Indiana University School of Medicine

15 March

NHS pilot for polygenic testing of UK patients suffering with hypercholesterolemia and familial hypercholesterolemia

21 February

Confirmation of board appointment

08 February

Positive results for Lipid inCode® in NHS clinical study

21 January

Proposed independent directorate appointment

10 January

FDA Pre-Submission filed for Cardio inCode-SCORE

2021

29 November

Directorate change

25 November

Trading and progress update

17 September

Grant of Share Options and PDMR dealing

16 September

Interim Results to 30 June 2021

10 September

Holding(s) in Company

02 September

Notice of Results

27 July

Holding(s) in Company

26 July

Positive Thrombo inCode clinical results

23 July

Holding(s) in Company

23 July

Holding(s) in Company

22 July

Admission to trading on AIM & First Day of Dealings

19 July

Investor presentation

Our Tests

UK/EU Tests

US Tests

SITAB

Investors

Investor Overview

Our Tests

UK/EU Tests

US Tests

SITAB

Investors

Investors

2024

2023

2022

2021

UK

SPAIN

US

COMPANY

WEBSITE

LANGUAGE